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INTRODUCTION
Renal failure is a major health issues worldwide. Acute kidney 
injury (AKI) results in an abrupt loss of renal function with a 
corresponding spike in serum creatinine concentration and 
decrease in urine output. Although AKI is a reversible condi-
tion, it can progress to chronic kidney disease (CKD), which is 
characterized by a reduced glomerular filtration rate. End-
stage renal disease (ESRD) is devastating condition, which re-
quires either renal transplantation or dialysis. Although kid-
ney dialysis replaces the renal filtration function by removing 
toxic substances from the blood and maintains survival of ESRD 
patients, it does not restore other kidney functions, such as 
erythropoietin production and vitamin D activation. Therefore, 
kidney transplantation is the only option to replace renal func-
tion in patients with ESRD. Unfortunately, donor shortage, sur-
gical morbidity and complications associated with the life-long 
usage of immune suppressants remain a continued problem. 
To address these unmet medical needs, several regenera-
tive medicine approaches have been proposed as possible so-
lutions. Regenerative medicine is a multidisciplinary field that 
combines various areas of science, including stem cell biolo-
gy, developmental biology, material sciences, and tissue engi-
neering. Various technologies developed in regenerative 
medicine have been applied for the restoration of kidney 
functions. Major research efforts in the regenerative medicine 
for kidney diseases include 1) identification of renal stem/
progenitor cells in embryonic and adult kidneys, 2) cell thera-
pies with hematopoietic, mesenchymal or fetal stem cells, and 
3) reconstruction of artificial kidneys or renal components by 
using primary renal cells, embryonic stem cells, or induced 
pluripotent stem cells (iPS).1 While many therapeutic interven-
tions appear to be effective in pre-clinical applications using 
animal models and a few clinical applications of AKI or CKD, 
challenges still exist in translating these promising outcomes 
in patients with kidney diseases. For example, despite the re-
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cent advances in cell-based therapies for the treatment of kid-
ney diseases, safety remains a continued concern, as direct in-
jection of the therapeutic cells can cause immune rejection, 
pulmonary embolism, and even teratoma formation in case of 
pluripotent cells.2,3 
It has been demonstrated that cells produce trophic factors 
that control regulation and function. These cellular products 
or secretomes present in the culture medium have been 
shown to be as effective as cellular therapies.2,4 As such, the use 
of cellular secretomes for therapy is an appealing alternative to 
cell-based options.2,4 Secretomes have been used as a form of 
conditioned medium (CM), where high levels of growth fac-
tors and tissue repairing chemokines from therapeutic cells 
are released into culture medium.4 Several studies demon-
strated favorable outcomes of CM therapy in kidney diseases 
using various types of cells including mesenchymal stem cells 
(MSC) and iPS.4 While the use of secretomes demonstrated a 
promising alternative to the cell-based therapy, many chal-
lenges need to be addressed before applying in the clinical set-
ting. The most critical issue involving the use of secretomes is 
attributed to the unidentified characteristic of the secreting fac-
tors.2 Further studies are needed to better characterize and de-
fine secretomes, which allows for improved control and regu-
lation for clinical translation.2 
Based on the pre-clinical therapeutic outcomes as described 
above,4 the CM secreted from the therapeutic cells is pre-
sumed to contain renotropic factors responsible for the kid-
ney repair. The renotropic factors include various bioactive 
molecules such as cytokines and growth factors that promote 
normal tubular cell differentiation, thus expected to replace 
lost and damaged tubular epithelial cells and function.1,5,6 This 
review covers the renotropic functions of bioactive com-
pounds that have potential to impact renal regeneration and 
protection based on the available data in the literature.
GROWTh faCTORs
hepatocyte growth factor
Hepatocyte growth factor (HGF) is a ligand for the c-Met re-
ceptor tyrosine kinase, which is known to have anti-apoptotic, 
mitogenic, motogenic, and morphogenic effects on renal tu-
bular cells, as well as angiogenic and angioprotective effects 
on endothelial cells.7 Sources of renal HGF are stromal cells 
such as mesangial cells, endothelial cells, and macrophages. 
In response to AKI, HGF secretion increases in distant organs 
such as lung and spleen as well as the injured kidney, and in-
crease in HGF plays a role in renal regeneration. HGF is a 
pleiotropic factor that plays an imperative role in tubular repair 
and regeneration after AKI. It is also known that HGF is also a 
renoprotective factor that exhibits a potent antifibrotic ability.8 
As chronic renal failure progresses, the expression of HGF de-
creases, but the expression of transforming growth factor-β 
(TGF-β) reciprocally increases.7 As is well known, TGF-β is a 
key factor in tissue fibrosis. Thus, decrease in HGF is associated 
with the aggravation of renal fibrosis and chronic renal failure. 
HGF’s morphogenic and motogenic effects were first de-
scribed in the Madin-Darby canine kidney cell line,9 and were 
also shown in other epithelial cells such as a visceral glomeru-
lar cell line, proximal tubular cell lines, and a medullary col-
lecting duct cell line.10-12 A unilateral nephrectomy model has 
been used to study the renotropic systems in compensatory 
renal regeneration. HGF mRNA and protein increase were ob-
served in the remaining kidney after unilateral nephrectomy, 
and this type of response was also shown in various models of 
acute renal injury caused by various nephrotoxins.13-15 Animal 
model experiments involving the treatment of supplements of 
exogenous HGF have shown preventive and therapeutic ef-
fects on injured kidneys. Kawaida, et al.16 demonstrated that 
intravenous injection of recombinant human HGF into mice 
prevented the deterioration of renal function caused by ad-
ministration of cisplatin or HgCl2. In addition, exogenous HGF 
promoted DNA synthesis of renal tubular cells following kid-
ney injuries caused by HgCl2 administration and unilateral 
nephrectomy, and induced regeneration of the normal renal 
tissue structure in vivo. These results suggest that HGF pre-
vents epithelial cell death, and promotes regeneration and re-
modeling of renal tissue against injury or fibrosis. Thus, HGF 
administration may be one treatment strategy to treat renal 
diseases.
Insulin-like growth factor-1
Insulin-like growth factor-1 (IGF-1) is a single-chain proinsu-
lin-like polypeptide, which consists of 70 amino acids. IGF-1 is 
a growth hormone (GH)-dependent growth factor, and it is 
thought that the growth-promoting and anabolic actions of 
GH are mediated by IGF-1.17 The circulating level of IGF-1 is 
controlled by GH. The collecting duct is a major source of IGF-
1 production in the adult kidney, and glomerular mesangial 
cells in culture also produce IGF-1. Receptors for IGF-1 are 
present in the glomeruli and on the basolateral membrane of 
the renal proximal tubular cell.18 The GH/IGF-1 system is es-
sential for normal kidney development and function. During 
embryogenesis, IGF-1 and -2 play important roles in normal 
metanephric development.19 During compensatory renal 
growth after unilateral nephrectomy, IGF-1 mRNA and protein 
expression was observed in the remaining kidney.20 
IGF-1 is also involved in the repair process following AKI. In 
an animal model, IGF-1 expression is increased in regenerat-
ing proximal tubule cells after acute injury, and IGF-1 treat-
ment accelerates recovery.21 Ding, et al.22 demonstrated that IGF-
1 treatment reduces protein catabolism and nitrogen excretion 
in rats with AKI as compared to rats not receiving IGF-1. More-
over, protein synthesis was increased and protein degradation 
was decreased in excised epitrochlearis muscle from IGF-
1-treated as compared to vehicle-treated rats. Miller, et al.23 
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also demonstrated a similar acceleration of recovery from 
ischemic AKI in rats receiving recombinant human IGF-1, 
and this was associated with increased rates of bromodeoxy-
uridine incorporation into proximal tubules. The beneficial ef-
fect of IGF-1 on post-ischemic renal injury could be explained 
by enhancement of glomerular filtration, renotropic property 
on renal tubules, and generalized anabolic action.18 However, 
clinical trials using IGF-1 in patients with AKI did not significant-
ly improve kidney function or overall outcomes. Nevertheless, 
Bach, et al.21 suggested that IGF-1 may potentially enhance 
stem cell-mediated repair of kidney injury.
Dysregulation of the IGF system has been implicated in vari-
ous kidney diseases such as diabetic nephropathy, polycystic 
kidneys, proteinuric CKD, etc.21 There is growing interest in 
stem cell therapy for kidney diseases. Some studies suggest 
that administered stem cells do not integrate into the kidney 
parenchyma, but likely act as a paracrine source of renotropic 
factors that ameliorate damage.21 In one study, MSC were shown 
to provide a protective effect on proximal tubular cell prolifera-
tion. This effect was mediated by IGF-1.24 A limitation of sys-
temic infusion of stem cells is their inability to home to injured 
tissues. Xinaris, et al.25 showed that preconditioning of MSC 
with IGF-1 before administration improved cell migration and 
restored normal renal function following AKI. Thus, it is sug-
gested that IGFs may have a potential role in facilitating stem 
cell repair of kidney injury. However, further studies are neces-
sary to determine the exact role of IGF-based therapies in kid-
ney disease.
Epidermal growth factor
Epidermal growth factor (EGF) is a 53-amino-acid peptide, and 
was first purified from human urine. EGF belongs to an exten-
sive class of molecules, referred to as growth factors, that me-
diates cell growth and differentiation, and also may stimulate 
acute cell responses.26 Their effects are mediated via autocrine, 
paracrine, or endocrine mechanisms. The distal tubule and 
medullary thick ascending limb of Henle’s loop are the pre-
dominant sites of EGF production within the adult kidney. 
Glomeruli, proximal tubules, medullary interstitial cells, and col-
lecting ducts all have EGF receptors. These receptors are present 
in the basolateral membranes of the tubular epithelial cells.18
Although the exact role of EGF in the kidney is unclear, its 
mitogenic effect on tubular cells has been suggested. EGF has 
been shown to be a mitogen for rabbit kidney cortical collect-
ing tubules, cortical thick ascending limbs of Henle, and prox-
imal tubule cells.26 The developing rat kidney produces TGF-β, 
which is a member of the EGF family of growth factors that 
acts through the EGF receptor. The growth and development 
of the metanephros in vitro is dependent on TGF-β.18,27 The 
possible involvement of EGF in compensatory renal hypertro-
phy has been also studied by immunoassay and in situ hy-
bridization.26 It has also been suggested that EGF may be im-
portant in maintaining the integrity of the epithelial surfaces 
of the urinary tract.28
Humes, et al.29 investigated whether exogenous EGF en-
hances the regenerative repair process to accelerate recovery 
of renal function after ischemic renal injury. They showed that 
exogenous EGF administration produced increases in renal 
thymidine incorporation compared with nontreated animals 
after ischemic injury, and this accelerated DNA replicative pro-
cess was associated with a return to near normal serum creat-
inine levels in EGF-treated animals several days earlier than 
that observed in nontreated animals. Miller, et al.23 showed that 
EGF reduces mortality in rats with ischemic renal injury, in 
addition to accelerating the restoration of normal renal func-
tion and improving histology. Other studies also demonstrated 
that EGF accelerates renal repair in a model of gentamicin or 
HgCl2 nephrotoxicity.30,31 These results suggest that exogenous 
EGF accelerates the repair process of the kidney after a severe 
toxic insult.
heparin-binding EGf-like growth factor
Heparin-binding EGF-like growth factor (HB-EGF) is a 20–22-
kD glycoprotein originally purified from conditioned media of 
a macrophage-like cell line, U937, and a member of the EGF 
superfamily of growth factors that signal through EGF-recep-
tor tyrosine phosphorylation.32 HB-EGF is expressed in mac-
rophages, T lymphocytes, vascular smooth muscle cells, endo-
thelial cells, keratinocytes, and intestinal epithelial cells.32 
Homma, et al.33 reported that HB-EGF mRNA could be in-
duced by acute renal injury in rat kidneys, and recombinant 
HB-EGF has a mitogenic impact on renal epithelial cells. Sakai, 
et al.32 suggested that HB-EGF is mainly produced in the distal 
tubules in response to acute injury and that endogenous HB-
EGF may be an important growth factor involved in the repair, 
proliferation, and regeneration of renal epithelial cells in the 
early stages of recovery. Another study showed that HB-EGF is 
an autocrine/paracrine factor that mediates the proliferation 
of renal proximal tubular cells.34
Vascular endothelial growth factor
Playing a pivotal role in angiogenesis, vascular endothelial 
growth factor (VEGF) promotes vascular proliferation and en-
dothelial cell repair. Its role in vascular proliferation is essen-
tial for not only developmental phases but also the recovery 
phase after an ischemic insult. VEGF has been shown to be 
strongly expressed in proximal tubular epithelium and podo-
cytes in both mouse and human kidneys.35 Basile, et al.36 dem-
onstrated that VEGF mRNA expression was repressed by great-
er than 50% of control values up to 3 days postischemia, while 
VEGF protein was repressed for up to 7 days postischemia in 
an ischemic-reperfusion injury rat model. The loss of endoge-
nous VEGF during a potentially critical window of the early re-
covery response suggested VEGF therapy could be a feasible 
renoprotective tool for ischemic renal injury. Leonard, et al.37 
evaluated whether recombinant VEGF administration could 
1018
Bioactive Compounds for Renal Disease
https://doi.org/10.3349/ymj.2018.59.9.1015
attenuate the progression of CKD in an ischemic-reperfusion 
injury rat model. When VEGF was given during the initial 2 
weeks post injury, interstitial scarring and albuminuria were 
significantly eliminated. However, this effect was not observed 
when VEGF administration was delayed until day 21. Chade 
and Kelsen38 published some experimental results using a re-
nal artery stenosis pig model, and suggested that damage and 
early loss of renal microvascular architecture is an important 
determinant of the renal injury progression in renal artery ste-
nosis and often initiates irreversible damage. In addition, in-
trarenal administration of VEGF preserved renal microvascu-
lar architecture and function of the stenotic kidney, and it 
preserved renal hemodynamics and function and decreased re-
nal fibrosis. This finding underlines the importance of renal mi-
crovascular integrity for renal function.39 A recent study showed 
VEGF added to amniotic fluid stem cells induced a significantly 
higher nephroprotection than amniotic fluid stem cells alone 
in rats with renal ischemia-reperfusion injury.40
Transforming growth factor-β
TGF-β superfamily includes four different isoforms (TGF-β1 
to TGF-β4) which share many structural and functional as-
pects. TGF-β is known to activate different downstream sub-
strates and regulatory proteins, induce transcription of various 
target genes that function in the differentiation, chemotaxis, 
proliferation, and activate many immune cells.41 Among the 
various biologic effects of TGF-β1, the most prominent feature 
is the regulation of extracellular matrix component synthesis 
by stimulation of extracellular matrix production, inhibition 
of enzymes that degrade matrix, and increase of the expression 
and adhesion phenotype of matrix receptors.42 TGF-β1 has 
been known to increase the synthesis of the components of ex-
tracellular matrix such collagen types I, II, III, IV, and V, proteo-
glycans, laminin, fibronectin, tenascin, and elastin.43 
Histologic features of most chronic renal diseases, includ-
ing diabetic nephropathy, focal segmental glomerulosclerosis, 
obstructive uropathy, and IgA nephritis, share thickened base-
ment membrane, accumulation of mesangial matrix, and glo-
merular and interstitial sclerosis. It has been well demonstrat-
ed that TGF-β1 plays a pivotal role in certain models of renal 
disease as a mediator of renal fibrosis.43 Border, et al.42 dem-
onstrated that addition of the neutralizing anti-TGF-β in vitro 
to glomerular cultures suppressed the synthesis of proteogly-
cans and fibronectin by 80%. Based on these results, they also 
showed in vivo administration of anti-TGF-β1 at the time of 
induction of the glomerular disease suppresses the increased 
production of extracellular matrix and significantly attenuates 
histological manifestations of the disease.44 Okuda, et al.45 dem-
onstrated that the renal protective effect of a protein restricted 
diet was through the suppression of TGF-β1 expression in an-
tithymocyte serum-induced nephritis model.
Platelet-derived growth factor
Platelet-derived growth factor (PDGF) was first isolated from 
platelets, where it is stored in the α-granules and released into 
the extracellular environment on platelet activation. However, 
it is also produced by other cell types, including smooth mus-
cle cells, macrophages, and mesangial, epithelial, and endo-
thelial cells of the kidney.43 PDGF is a well-characterized fac-
tor that promotes fibrosis in many diseases and organs, 
including the kidney, and it is one of the most potent mito-
gens for mesangial cells in culture.43,46 Glomerular mesangial 
cells proliferate in response to glomerular damage, and this 
response is regarded as a risk factor for the progression of glo-
merular nephritis to irreversible glomerular scarring and a 
variety of glomerular diseases. There is also evidence to sug-
gest an involvement of PDGF in the regulation of renal extra-
cellular matrix turnover, the chemoattraction of mesangial 
cells and/or other cells to sites of injury, the regulation of glo-
merular hemodynamics, and lipoprotein uptake in the glom-
erulus.47 Therefore, understanding regulatory mechanisms 
that control proliferation of mesangial cells is important in de-
veloping effective treatments for glomerular disease. Bessho, et 
al.48 demonstrated that HGF suppressed PDGF-induced prolif-
eration of activated mesangial cells both in vivo and in vitro. 
Meanwhile, the immunoreactivity of PDGF-B was demon-
strated in the immature tubules of the developing human kid-
ney, suggesting that PDGF-B would be involved in the tubulo-
genesis.49 In addition, Nakagawa, et al.50 reported that the PDGF-
B/PDGFRs axis is involved in the proliferation of injured tubular 
cells and plays an important role in the regeneration of tubular 
cells from acute ischemic injury.
Bone morphogenetic protein-7
The TGF-β superfamily includes more than twenty types of 
bone morphogenetic proteins (BMPs), of which BMP-7 (also 
called as osteogenic protein-1) is closely involved in kidney 
development and disease. BMPs are differentially expressed 
throughout development. BMP-7 is initially expressed in the 
ureteric bud. In the development period, BMP-7 is also found 
in the metanephric mesenchyme, early tubules, and in the 
podocytes of mature glomeruli. In the adult kidney, BMP-7 is 
expressed in glomerular podocytes, the thick ascending limb, 
the distal convoluted tubule, and the collecting duct.51 As pre-
viously mentioned, TGF-β1 is consistently upregulated in mod-
els of experimental and human renal fibrosis. On the contrary, 
BMP-7 expression was markedly reduced in experimental dis-
eases associated with renal fibrosis. Several studies showed 
that the expression of BMP-7 mRNA and protein was marked-
ly reduced in the medullar and glomeruli after AKI and uni-
lateral ureteral obstruction.52-54 De Petris, et al.55 demonstrated 
that culture of mouse podocytes under high glucose decreases 
synaptopodin, podocin and BMP-7 transcription and protein 
synthesis compared to normal glucose.
An antifibrotic effect of BMP-7 in renal cells has been shown. 
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BMP-7 proved to be a potent inhibitor of TGF-β1 induced epi-
thelial-to-mesenchymal transition of proximal tubular epithe-
lial cells.56 BMP-7 also represses the basal and tumor necrosis 
factor-α (TNF-α)-stimulated expression of the pro-inflamma-
tory cytokines interleukin (IL)-6 and IL-1β, the chemokines 
monocyte chemoattractant protein 1 (MCP-1) and IL-8, and 
the vasoconstrictor endothelin 2 (ET-2) in proximal tubular 
epithelial cells.57 In cultured mesangial cells, BMP-7 reduces 
TGF-β-induced extracellular matrix protein accumulation 
primarily by maintaining levels and activity of matrix metallo-
protease-2.58 BMP-7 is a differentiation and survival factor for 
podocytes, it can also inhibit adverse effect on podocytes 
caused by high glucose.59
In one study, Vukicevic, et al.60 demonstrated that intrave-
nous BMP-7 treatment reduced severity of renal injury after 
AKI in rats. BMP-7 treatment inhibited tubular epithelial dis-
ruption after unilateral ureteral obstruction, preventing tubu-
lar atrophy and diminishing the activation of tubulointerstitial 
inflammation and fibrosis and preserving renal function.53 
Morrissey, et al.61 showed that intraperitoneal BMP-7 treat-
ment is capable of blunting the progression of fibrotic disease 
and of decreasing interstitial volumes in a rat model of unilat-
eral ureteral obstruction. Of note, a return of renal function is 
accelerated by BMP-7 treatment. In streptozotocin-induced 
diabetic rats, both glomerular and tubulointerstitial damage 
as well as albuminuria were significantly attenuated by BMP-
7 therapy in a dose-dependent manner.62 BMP-7 treatment at-
tenuated progression of renal disease even in the genetic mouse 
models of lupus nephritis and Alport syndrome.56 These results 
suggest that BMP-7 administration may be a potential treat-
ment to restore or preserve renal function.
Granulocyte-colony stimulating factor
A recent discovery in stem cell research has shown multi-lin-
eage plasticity of bone marrow cells and the contribution of he-
matopoietic stem cell for the regeneration of damaged organs 
including the kidney. This finding suggests the use of granulo-
cyte-colony stimulating factor (G-CSF) as a therapeutic option 
to regenerate wounded organs.63 G-CSF mRNA and protein 
expression was shown in thick ascending limb cells of the kid-
ney after renal AKI in mice, and increased peripheral serum 
concentration of G-CSF was also noted. This suggests a possi-
ble communication from the injured kidney to the bone mar-
row.64 Several studies have described the effect of exogenous 
G-CSF on kidney function in an AKI animal model.65-67 Some 
studies reported that G-CSF treatment has a favorable effect 
on the course of AKI as compared with control group.65,66 
However, Tögel, et al.67 showed that boosting of peripheral 
stem cell numbers by G-CSF was associated with increased se-
verity of renal failure and mortality in an AKI model. In addi-
tion to these contradictory results, there is still controversy re-
garding the mechanisms by which G-CSF exerts an alleviative 
effect on renal injury. The conflicting results of these studies 
with experimental AKI models suggested complex effects of 
G-CSF on the kidney. G-CSF can become a two-edged sword 
after kidney injury; it exerts both mitigating and detrimental ef-
fects at the same time.63 A careful observation of renal function 
is necessary when G-CSF is used in patients with renal injury.
CyTOKINEs
stromal derived factor-1/C-X-C chemokine receptor 
type 4 (CXCR4) axis
Chemokines are small molecules involved in the regulation of 
inflammation and cell migration. Chemokines are known to 
possess the ability to induce directed chemotaxis in nearby re-
sponsive cells. C-X-C chemokine receptor type 4 (CXCR4) is a 
principal receptor for stromal derived factor-1 (SDF-1), and re-
cently the role of CXCR4 has been highlighted in a variety of 
cancer and acquired immune deficiency syndrome.68 CXCR4 
is one of the major receptors that regulate trafficking of hema-
topoietic and tissue stem cells and progenitor cells. It is also 
known to guide CXCR4-positive cells during embryogenesis, 
development and tissue regeneration. Furthermore, CXCR4 is 
involved in the regulation of angiogenesis through recruitment of 
endothelial progenitor cells. The recruitment of CXCR4-posi-
tive progenitor cells is mediated by hypoxic gradients via hy-
poxia-inducible factor 1 (HIF-1)-induced expression of SDF-1.69
SDF-1 and CXCR4 expression was observed in the develop-
ing kidney. CXCR4 expression was limited to focal expression 
by extravascular cells positive for the stem cell antigen CD34. 
SDF-1 expression observed in the ureteric buds, S-shaped bod-
ies, and glomerular mesangium suggests a potential “gradi-
ent” of SDF-1 expression.70 Tögel, et al.71 evaluated the expres-
sion pattern and functions of the SDF-1/CXCR4 system in normal 
kidney and in the kidney after ischemia-reperfusion injury. 
SDF-1 and CXCR4 are expressed in normal kidney mostly by 
distal tubular cells in the cortex, whereas all kidney regions 
show robust expression of SDF-1 and CXCR4 after kidney in-
jury induced by ischemia-reperfusion. Stokman, et al.72 dem-
onstrated that renal SDF-1 protein increased significantly in the 
early phase of ischemia-reperfusion injury, and antisense treat-
ment resulted in a reduction of corticomedullary SDF-1 expres-
sion, which was accompanied by severely increased tubular 
injury and decreased renal function. Ohnishi, et al.73 provided 
the evidence that incorporation of bone marrow-derived cells 
in endothelial and smooth muscle cells was evident in an ear-
ly stage of ischemic kidney injury, and anti-CXCR4 antibody 
decreased the numbers of infiltrated bone marrow-derived 
cells. These data suggest that SDF-1/CXCR4 axis may play a 
protective and reparative role in AKI model. Therefore, renal 
SDF-1 is one of the important mediators of migration and hom-
ing of CXCR4-positive cells targeting the injured kidney. 
IL-22
Interleukins are a group of cytokines that were first seen to be 
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expressed by white blood cells (leukocytes), and they have be-
come well-known regulators of innate and adaptive immuni-
ty-related tissue inflammation. IL-22 is exclusively produced 
by different immune cell subsets, whereas IL-22 receptors are 
mainly expressed by epithelial cells in various tissues includ-
ing the kidney. IL-22 primarily targets nonhematopoietic epi-
thelial and stromal cells, where it can promote proliferation and 
play a role in tissue regeneration. Recently, IL-22 has gained at-
tention due to its unique ability to maintain and restore epithe-
lial integrity.74,75 
Kulkarni, et al.76 used an in vitro system to screen for the im-
pact of interleukins on post-ischemic epithelial healing, and 
found that recombinant IL-22 had the strongest proregenera-
tory effect on tubular epithelial cells. They suggested that ne-
crotic cell-derived Toll-like receptor 4 agonists activate intrare-
nal mononuclear cells to secrete IL-22, which accelerates tubular 
regeneration and recovery in AKI. Xu, et al.77 demonstrated that 
intraperitoneal administration of recombinant IL-22 amelio-
rates renal ischemia reperfusion injury in mice model, and 
preserves renal functions by activating signal transducer and 
activator of transcription 3 (STAT3) and AKT in the proximal 
tubular epithelial cells. Taken together, these results suggest 
that IL-22 might also have therapeutic potential for the treat-
ment of acute ischemic kidney injury.
hORmONEs
angiotensin II
Angiotensin is a peptide hormone that causes vasoconstric-
tion, thus resulting in increased blood pressure. The intrarenal 
renin-angiotensin system is known to have a major impact on 
tubular cell proliferation, apoptosis and regeneration follow-
ing kidney injury.78 Tissue repair involves inflammatory cells 
and myofibroblasts. Inflammatory cells include members of 
the monocyte/macrophage lineage and are integral to the ini-
tiation of the repair process, while myofibroblasts are pheno-
typically transformed interstitial fibroblasts that are responsi-
ble for collagen turnover and fibrous tissue formation. In the 
microenvironment, de novo generation of angiotensin II is in-
volved.79 In an autocrine/paracrine manner, this peptide regu-
lates expression of TGF-β1 via angiotensin (AT1) receptor-ligand 
binding. Angiotensin-converting enzyme (ACE) inhibition or 
AT1 receptor antagonism prevent many of these molecular 
and cellular responses that lead to fibrosis.
Drugs that reduce glomerular hypertension and protein 
trafficking prevents renal function decline and facilitate kid-
ney repair. The objective of the current treatment is inhibition 
of the renin-angiotensin system by ACE inhibitors (ACEi) and 
angiotensin II type I receptor blockers (ARBs). Nondiabetic 
and diabetic nephropathic animal models have clearly shown 
that treatment with ACEi, ARBs, or their combination prevents 
progressive renal damage, and also promotes the regression of 
glomerulosclerosis and vascular lesions.80,81 
Erythropoietin
Erythropoietin is a hormone produced largely in the kidney, 
and it regulates red blood cell production in the hematopoiet-
ic system. Erythropoietin is known to be involved in wound 
healing responses, angiogenesis, and the body’s innate re-
sponse to injury in the brain and heart. In particular, renopro-
tective effects of erythropoietin during AKI and nephrotoxic 
agent-induced injury have been also suggested.82 In an isch-
emic-reperfusion injury animal model, erythropoietin treat-
ment was shown to reduce the extent of renal dysfunction; this 
renoprotective effect was associated mainly with a reduction 
in apoptotic cell death.83-85 Similar results were also shown in 
nephrotoxic agent-induced kidney injury model. Bagins, et al.86 
demonstrated that erythropoietin significantly enhanced the 
recovery from AKI induced by cisplatin via stimulation of tu-
bular cell regeneration. Lee, et al.87 showed that erythropoietin 
effectively attenuated renal interstitial inflammation and fibro-
sis in chronic cyclosporine nephropathy. Recently, a pilot clini-
cal study suggested a beneficial effect of erythropoietin on the 
prevention of AKI. Prophylactic administration of erythropoi-
etin prevents AKI and improves postoperative renal function in 
patients who underwent coronary artery bypass grafting; how-
ever, another study failed to reproduce this positive effect.88,89
melatonin 
Melatonin is a circadian-regulating hormone mainly secreted 
by the pineal gland. Recent studies have shown that melato-
nin has a variety of biological functions, including anti-oxida-
tive stress, anti-inflammatory, anti-apoptosis, and anti-tumor 
properties.90 It has been reported that intraperitoneal injec-
tion of melatonin can reduce kidney damage induced by AKI 
and unilateral ureteral obstruction mainly through the anti-
oxidant and anti-apoptotic effects.91,92 
OThER COmPOUNDs
activin a/follistatin
Activin A, a member of the TGF-β superfamily, inhibits branch-
ing tubulogenesis of the kidney in organ culture system as well 
as in an in vitro tubulogenesis model. Follistatin is an antago-
nist of activin A, also known as activin-binding protein. It can 
block the effect of activin A on kidney development, plays an 
important role in branching tubulogenesis, and also promotes 
tubular regeneration after AKI by blocking the action of en-
dogenous activin A.93 HGF is also known to inhibit the produc-
tion of activin A, resulting in branching tubulogenesis.93 Fang, 
et al.94 showed the evidence that activin B is also involved in 
ischemic reperfusion injury rat model, and proposed that ac-
tivin B initiates and activin A potentiates renal injury after isch-
emic reperfusion injury. In a murine study, exogenous admin-
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istration of follistatin prevented the histologic changes after 
ischemic kidney injury, reduced apoptosis in tubular cells, and 
accelerated tubular cell proliferation. Laboratory results on 
renal function were favorable in follistatin-treated rats.95 In a rat 
model of unilateral ureteral obstruction, activin A produced by 
interstitial fibroblasts acts as a potent profibrotic factor during 
renal fibrosis, administration of recombinant follistatin re-
duced the fibrotic area in the unilateral ureteral obstruction 
kidneys.96 
Galectin-3
Galectins constitute a large family of β-galactoside binding lec-
tins, and galectin-3 is known to promote cell migration by 
modulating cell-cell adhesion and cell-matrix adhesion which 
are critical aspects for embryogenesis, inflammation as well as 
for cancer dissemination.97 It is strongly expressed in the ure-
teric bud and its derivatives, and its upregulation is critical 
in controlling the ureteric bud branching, thus it promotes 
nephrogenesis during development.98 Galectin-3 has also been 
reported to play a role in ameliorating ischemic and nephro-
toxic AKI. There was significant negative correlation between 
galectin-3 mRNA expression and serum creatinine at 48 hours 
after an ischemic-reperfusion injury. In later stages of regen-
eration, galectin-3 expressions were found in macrophages, 
suggesting that galectin-3 may play an important role in acute 
tubular injury and the following regeneration stage.99 On the 
one hand, galectin-3 is associated with fibrosis in a variety of or-
gans such as liver, skin, lung, gut, myocardium, vascular, pan-
creas, and it also plays a pivotal role in interstitial fibrosis and 
progression of CKD. Elevated plasma galectin-3 levels are also 
associated with increased risks of rapid renal function decline, 
incidence of CKD, and progressive renal impairment.97,98 Ga-
lectin-3 has been proposed as a potential therapeutic target 
for the treatment of CKD, and currently clinical trials using a 
galectin-3 inhibitor are under investigation.98,100 
Vitamin E
While vitamin E has various biological functions including en-
zymatic activity, gene regulation, and inhibition of platelet ag-
gregation, the most important role of vitamin E is considered 
to be its antioxidant effect. Reactive oxygen species have been 
known to play an important role in the development of AKI.101 
Vitamin E is able to bind to various reactive oxidant species such 
as superoxide free radicals, and it is possible to prevent dam-
age caused by reactive oxygen species. The protective effect of 
vitamin E against AKI was first reported more than 2 decades 
ago, thereafter therapeutic action of vitamin E has been dem-
onstrated in dozens of studies using a variety of AKI model in-
duced by ischemia-reperfusion, nephrotoxic drugs, and con-
trast agents, etc.101 A meta-analysis suggested that vitamin E 
plus hydration significantly reduced the risk of contrast-in-
duced AKI in patients with renal impairment compared with 
hydration alone.102 However, several researchers maintained 
that a single vitamin E administration did not have a benefi-
cial effect on the prevention and severity of AKI, as the oxida-
tive stress in the kidney tissue could not be absolutely related 
to renal dysfunction in some AKI models.103 According to a re-
cently published network meta-analysis, vitamins and ana-
logues have a preventive effect on contrast-induced AKI com-
pared to hydration, but high-dose statins plus hydration with or 
without N-acetylcysteine is shown to be the most effective way 
to prevent the development of AKI.104 Thus, the combination 
of vitamin E and other therapy factors such as other vitamins, 
amino acids, drugs, and cells could be novel optimized meth-
ods, it should be elucidated through the experimental and clin-
ical investigation in the future.
CONCLUDING REmaRKs
Herein, we summarized the role of various bioactive com-
pounds that are associated with kidney regeneration (Table 1). 
Although many renotropic factors or signaling pathways have 
been identified, the mechanisms of these factors are not fully 
understood. It is still unclear how these compounds interact 
with injured kidney tissues for repair. To obtain better under-
standing about the renotropic systems, determination of more 
precise mechanisms of how renal cells recognize and respond 
to renal injury is required. It would be valuable if these bioac-
tive compounds promote renal regeneration via the activation 
of intrinsic renal stem cells. For example, recent studies have 
demonstrated evidences of the activation and infiltration of 
host stem or progenitor cells through delivery of bioactive fac-
tors and the concept of tissue regeneration, namely in situ tis-
sue regeneration, may be used for efficient kidney regenera-
tion.105 The in situ tissue regeneration utilizes the body’s natural 
healing capacity to repair damaged tissue or organs, and re-
quires the safe and targeted in vivo delivery of the bioactive fac-
tors for enhanced therapeutic outcomes. Precise and well-con-
trolled release of the growth factor or cytokines through various 
types of delivery vehicles such as hydrogel will be a crucial fac-
tor for efficient kidney repair.106 In conclusion, the therapeutic 
option using renotropic factors holds significant promise for 
treatment of kidney diseases. The understanding and utiliza-
tion of bioactive compounds can play an important role in the 
success of these treatments and should be carefully considered 
in future therapies.
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